Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.
about
Biomarkers and biometric measures of adherence to use of ARV-based vaginal ringsHow Stigma Surrounding the Use of HIV Preexposure Prophylaxis Undermines Prevention and Pleasure: A Call to Destigmatize "Truvada Whores"Combination HIV prevention interventions: the potential of integrated behavioral and biomedical approachesDivergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) studyAntiretroviral Drug Use and HIV Drug Resistance Among HIV-Infected Black Men Who Have Sex With Men: HIV Prevention Trials Network 061Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitibine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010.MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartmentsWomen's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South AfricaAntiretroviral Drug Use in a Cohort of HIV-Uninfected Women in the United States: HIV Prevention Trials Network 064Personalized Biobehavioral HIV Prevention for Women and Adolescent Girls.Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence.Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.Preventing HIV infection in women.Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection.Topical microbicides and HIV prevention in the female genital tractPerspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa.Perspectives on HIV prevention among urban black women: a potential role for HIV pre-exposure prophylaxis.Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism.Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study.Preparing for the unexpected: the pivotal role of social and behavioral sciences in trials of biomedical HIV prevention interventions.Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level in MTN-001: Comparison Between Vaginal Gel and Oral Tablets in Two Geographic RegionsEstimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies.Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women.Summary measures of adherence using pill counts in two HIV prevention trials: the need for standardisation in reportingNondisclosure of HIV status in a clinical trial setting: antiretroviral drug screening can help distinguish between newly diagnosed and previously diagnosed HIV infection.Adherence to post-exposure prophylaxis for non-forcible sexual exposure to HIV: a systematic review and meta-analysis.How acceptable are antiretrovirals for the prevention of sexually transmitted HIV?: A review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention.Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection.Effects of partnership change on microbicide gel adherence in a clinical trial (HPTN 035).Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature.Methodological lessons from clinical trials and the future of microbicide research.Factors Supporting and Hindering Adherence to Rectal Microbicide Gel Use with Receptive Anal Intercourse in a Phase 2 Trial.How Presentation of Drug Detection Results Changed Reports of Product Adherence in South Africa, Uganda and Zimbabwe.Acceptability and use of a dapivirine vaginal ring in a phase III trial.Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B).Demographic Differences in PrEP-Related Stereotypes: Implications for Implementation.End-Users' Product Preference Across Three Multipurpose Prevention Technology Delivery Forms: Baseline Results from Young Women in Kenya and South Africa.Women and ARV-based prevention: opportunities and challenges.Exploring acceptability of oral PrEP prior to implementation among female sex workers in South Africa.Comparison of the Pharmacokinetics and Pharmacodynamics of Single-Dose Tenofovir Vaginal Film and Gel Formulation (FAME 05).
P2860
Q26753097-B5F3C110-5FBE-4EC6-8F44-D86A116ADCC0Q26798250-C6FF7196-4F01-47AD-B127-85F27BF8DD6EQ27005602-8A5DE43E-04E5-4BAC-B02D-48EDE0E9D952Q27300707-2F1BF218-AD36-4377-91FF-D29E95868413Q27312940-82758A0C-3022-4683-904B-72CE694D0264Q27318158-D66D4202-E74E-416F-A088-A71249D8EF26Q28485356-8DE57D63-2384-4088-A1C5-2EFE0B6D2FAFQ28540042-73949B82-5D50-4FEE-B842-D64108515448Q28550081-FD9E7F04-9C45-44D7-B853-37BCC91763AFQ30357818-B81C0665-BCC5-4D1A-8AC0-901E234ADD59Q33765789-8EE8A392-5B47-4B9C-99C4-07C54C5653F6Q33821090-3AFCAE83-5A30-432E-B5F4-BEFDE083DEE1Q33855156-8A86A201-2467-43DC-8988-DCE06FF3FCC5Q33948938-92C48617-04E4-4903-988C-2BDC7BDE20F9Q34086820-42B5F489-35EA-4BFC-9E4F-2A2E51FAF858Q34180615-2AE1F2A9-EE8B-4E66-A5B8-7139C57C66A4Q34606593-4BD139EA-691C-4198-9FC0-C0F46C2CE45BQ34658079-C46BAE0B-ABFA-4D7B-ACCE-40D679B8FE78Q36952395-844EEE19-7BDF-467E-8038-35309F6813C4Q37080439-720ADDA0-244F-4775-BE78-3FA8B119AC1BQ37118864-2202D635-7463-44C0-BD5A-FC7BCB100606Q37210864-632F7752-D484-4985-9B40-58A6428A1C97Q37224902-E6769B04-49A6-4457-8D34-B9D90E651F29Q37265920-204FF7F2-66E3-489B-987E-2C871EA4A629Q37395586-93E6D6BB-DF9C-4729-B90A-A0287DB72E7DQ37395830-4E1FF8C9-80E2-4B37-BBB8-F8EB8B83DD80Q37526187-081E8447-1BD1-4496-8AFE-EA1C69DE62E2Q37626085-9F5C9D99-9CCA-405D-89D7-C6E2A197A66CQ37705259-B3A67784-04A0-4AB3-B57C-14B730135D79Q37736077-4824D93D-E54C-42F3-9FB1-3AD37B10F7C8Q38062882-62C3A613-965E-4417-AD35-334DE7F01427Q38616485-7620D5A0-D0E2-44CD-9A5A-82A8F5222825Q38767384-3435B4D5-2A93-41F0-94C7-22C39A68EEC2Q38850472-DE126073-483D-498F-AFCC-698B8552A933Q40465731-5B681E5A-56DB-4A80-8A85-1166AB35F5E5Q41122508-AD9412D6-F69E-4E95-AC02-A068A077122FQ45980808-62CFBF12-DA8F-4489-ABA3-90DB6163CFABQ46553256-80B48A49-898A-4693-A4CD-58DCECDC94A7Q49850256-B7BF69BD-11F9-4DE2-8A5A-BE7AFFAC4C6EQ50028271-C4F7991D-289A-4B47-AFFE-6687F192A378
P2860
Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Adherence and acceptability in ...... r for HIV prevention in women.
@ast
Adherence and acceptability in ...... r for HIV prevention in women.
@en
type
label
Adherence and acceptability in ...... r for HIV prevention in women.
@ast
Adherence and acceptability in ...... r for HIV prevention in women.
@en
prefLabel
Adherence and acceptability in ...... r for HIV prevention in women.
@ast
Adherence and acceptability in ...... r for HIV prevention in women.
@en
P2093
P2860
P1433
P1476
Adherence and acceptability in ...... r for HIV prevention in women.
@en
P2093
Alexandra M Minnis
Barbra A Richardson
Beatrice A Chen
Clemensia Nakabiito
Craig Hoesley
Craig W Hendrix
Jessica Justman
Kailazarid Gomez
Karen Patterson
Lydia Soto-Torres
P2860
P2888
P304
P356
10.1007/S10461-012-0333-8
P577
2013-02-01T00:00:00Z